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Induced pluripotent stem cells (iPSCs) can be gener-
ated from differentiated human and mouse somatic
cells using transcription factors such as Oct4, Sox2,
Klf4, and c-Myc. It is possible to augment the reprog-
ramming process with chemical compounds, but
issues related to low reprogramming efficiencies
and, with a number of protocols, residual vector
sequences, remain to be resolved. We show here
that it is possible to reprogram mouse and human
cells to pluripotency by direct transfection of mature
double-stranded microRNAs (miRNAs). Our ap-
proaches use a combination of mir-200c plus mir-
302 s and mir-369 s family miRNAs. Because this re-
programming method does not require vector-based
gene transfer, it holds significant potential for bio-
medical research and regenerative medicine.
Induced pluripotent stem cells (iPSCs) can be directly generated
from fibroblast cultures by expression of only a few defined
factors, such as Oct4, Sox2, Klf4, and c-Myc (Takahashi and
Yamanaka, 2006). Since the initial description of this approach,
numerous studies have described modifications of the original
protocol using additions or alternatives to these factors, in-
cluding small molecules, with the aim of improving the efficiency
and/or moving it toward potential clinical application (for
example, Huangfu et al., 2008a, 2008b; Yoshida et al., 2009;
Judson et al., 2009; Esteban et al., 2010). Genomic modification
also remains a concern, because viral vector-mediated trans-
duction of reprogramming genes involves random insertions of
exogenous sequences into the genome. Some recent studies
have indicated that iPSCs can be obtained with virus-free,
removable PiggyBac transposons or episomal systems (Okita
et al., 2008; Kaji et al., 2009; Woltjen et al., 2009; Jia et al.,
2010), but these approaches still use DNA constructs, so the
possibility of genomic integration of introduced sequences
remains. Sendai virus has been used as an alternative (forexample, in Seki et al., 2010), because it has an RNA genome,
but it is still a virus. Reprogramming using just protein or
mRNA has also been reported, but the protocols involved are
technically challenging (Kim et al., 2009; Zhou et al., 2009;
Warren et al., 2010).
MicroRNAs (miRNAs) are well-characterized regulators of
development and differentiation (Lee et al., 1993; Ruvkun,
2001). Recent reports have demonstrated that specific miRNAs
are highly expressed in embryonic stem cells (ESCs) and play
a critical role in the control of pluripotency-related genes (Hou-
baviy et al., 2003; Judson et al., 2009; Suh et al., 2004). To iden-
tify candidate miRNAs to test for reprogramming activity, we
analyzed miRNA expression in mouse ESCs, mouse iPSCs,
and adult mouse adipose stromal cells (mASCs). miRNAs that
were expressed >2-fold more strongly in mouse iPSCs and
ESCs relative to mASCs (Figure S1A available online) were
used for subsequent transfection assays (Figure S1D). The trans-
fection efficiency was assessed by fluorescence microscopy
using Fluorophore-labeled miRNAs, and we determined that
75.1% ± 0.1% of cells were fluorescent positive (data not
shown). We introduced the miRNAs into mASCs obtained from
Nanog promoter-driven green fluorescent protein (GFP) reporter
mice (Okita et al., 2007). Real-time RT-PCR analysis indicated
that transfected miRNA levels decreased markedly 72 hr post-
transfection, so the transduction method was optimized to
include four transfections at 48 hr intervals (Figures S1B and
S1C; Table S1A available online). Eight days after initial transfec-
tion, the cells were passaged and grown in ESC-maintaining
medium. We were able to detect GFP expression on day 14 after
the transfection of mir-200c, mir-302 s, and mir-369 s family
miRNAs, and by day 15 we observed approximately five GFP-
positive colonies from 5 3 104 cells (Figures 1A–1D), giving an
apparent efficiency that is comparable to that seen with the orig-
inal report of retrovirus-mediated transcription factor introduc-
tion (Takahashi and Yamanaka, 2006). These colonies were not
seen in mock transfectants in which negative control miRNAs
were introduced (data not shown). Our analysis showed that
introduction of all three of these miRNA candidates into mASCs
from Nanog reporter mice successfully generated GFP-positive
colonies, whereas the transduction of just one or two factors inCell Stem Cell 8, 633–638, June 3, 2011 ª2011 Elsevier Inc. 633
Figure 1. Induction of ES-like Cells from mASCs Using miRNAs
(A–D) Morphology of transfected mASCs. At day 15, colonies with defined margins and round shapes (C and D) that were distinct from parental cells (A and B)
were observed. Brightfield (left) and fluorescence (right) images of parental and transfected cells are shown.
(E) The mi-iPSCs (clone 311) expressed undifferentiated ESC-marker genes. The expression of mRNA copies was normalized against GapdhmRNA expression
(mean ± SEM; n = 3).
(F–I) Immunocytochemistry revealed mi-iPSCs expressing Ssea-1 (F and G) and Oct4 (H and I).
(J) The expression of miRNA copies was normalized against U6 expression (mean ± SEM; n = 3).
(K–O) The differentiation of mi-iPSCs was induced by EB-like formation. The morphology of EB-like formation is shown in Figure S2D. (K) Real-time RT-PCR
analysis verified the expression of differentiation markers, such as Alb, Fabp4, andGfap. The expression of mRNA copies was normalized againstGapdhmRNA
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ure S1D).We thus used all three candidates,mir-200c,mir-302 s,
and mir-369 s, in subsequent studies. We refer to the reprog-
rammed cells generated using this approach as miRNA-induced
pluripotent stem cells (mi-iPSCs).
Real-time RT-PCR (Table S1B) data revealed that on post-
transfection day 30, mi-iPSCs expressed several genes charac-
teristic of undifferentiated ESCs, such as Nanog, Oct4, Sox2,
Cripto, Dppa5, and Fbx15 (Figure 1E). The mi-iPSCs also
expressed ESC-specific markers, such as Ssea-1 and Oct4
(International Stem Cell Initiative et al., 2007; Takahashi and
Yamanaka, 2006) (Figures 1F–1I). In addition, greater mir-200c,
mir-302 s, and mir-369 s expression was observed in mi-iPSCs
than in the parental cells (Figure 1J). Expression profiling re-
vealed the greater similarity of mi-iPSCs to mouse iPSCs (Taka-
hashi and Yamanaka, 2006) and ESCs than mASCs (Figure S2E;
accession number GSE28586). Karyotype analysis showed
that 66.7% of the cells had a normal chromosome complement
(40 mouse chromosomes in 8/12 cells) (Figure 1T).
To evaluate the differentiation capacity of mi-iPSCs, we exam-
ined the formation of embryoid bodies (EBs) in floating culture
(Zhou et al., 2009) (Figure S2D). In suspension culture, mi-iPSCs
formed ball-shaped EB-like structures. We transferred them to
primary culture conditions (PCCs) consisting of gelatin-coated
plates maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS). Attached
cells, which we termed post-mi-iPSCs, were analyzed as
described below and were compared with mi-iPS and parental
cells. Twenty days after transfer to PCCs, the post-mi-iPSCs
exhibited various morphological changes and expressed several
genes characteristic of differentiation into all three germ layers.
Real-time RT-PCR analysis confirmed Alb (endoderm), Fabp4
(mesoderm), and Gfap (ectoderm) expression in post-mi-iPSCs
(Figure 1K). The expression level of ES-like genes that were
highly expressed in ESCs and mi-iPSCs was significantly
reduced in post-mi-iPSCs (Figure S2A). Immunocytochemistry
detected post-mi-iPSCs that were positive for Alb, aSma (meso-
derm), Tubb3 (ectoderm), and Gfap (Figures 1L–1O and S2B).
mir-200c and mir-302 s miRNA expression was lower in post-
mi-iPSCs than in mi-iPSCs and ESCs (Figure S2C).
We next performed bisulfite genomic sequencing analyses to
study the methylation status of cytosine guanine (CpG) dinucle-
otides in the promoter regions of pluripotency-associated genes,
such as Nanog and Oct4 (Table S1C; Zhou et al., 2009). The
results revealed that the CpG dinucleotides of these gene
promoters were less frequently methylated in mi-iPSCs andexpression (mean ± SEM; n = 3). (L–O) Two weeks later, attached post-mi-iPSC
expression of Alb (L), aSma (M), Tubb3 (N), and Gfap (O) in these cells.
(P)Nanog andOct4were not appreciablymethylated inmi-iPSCs (clones 311 and
and post-mi-iPSCs (open and closed circles indicate unmethylated and methyla
(Q) mi-iPSCs were subcutaneously transplanted into the dorsal flanks of NOD/S
(endoderm), epidermal (ectoderm), and adipose (mesoderm) layers.
(R) Chimericmice were gauged by coat color. Genotyping of the chimeric mice de
tissues. Il-2 was used as an internal control. Tail tips of a Nanog reporter mous
respectively. Tg, transgene characteristic of Nanog reporter mice; PC, positive c
(S) Germline transmission. The crossing of chimeric mice (>70% BL6 hair color c
mice at a frequency identical to that observed in the original murine mi-iPSC stra
(T) The karyotype of human and mouse mi-iPSCs. Forty-six chromosomes in hu
See also Figures S1 and S2 and Tables S1 and S2. Bar = 100 mm; original magnESCs than in post-mi-iPSCs and parental cells (Figure 1P). These
findings are consistent with reactivation of the promoter regions
of immature status-related genes in mi-iPSCs.
To examine their in vivo differentiation properties, mouse
mi-iPSCs were subcutaneously transplanted into the dorsal
flanks of nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mice. Teratoma formation was observed in mice
12 weeks postinjection (Figure 1Q). Histological analysis re-
vealed that the tumors contained various tissues found in epithe-
lial (endoderm), epidermal (ectoderm), and adipose (mesoderm)
tissues. Furthermore, the injection of blastocysts with mi-iPSCs
resulted in the generation of chimeric mice (Figure 1R and
Table S1D). Genotyping (Table S1E) of the chimeric mice
demonstrated the contribution of mi-iPSCs in intestinal, brain,
adipose, and gonadal tissues, i.e., across all three germ layers.
Crossing the chimeric mice resulted in the generation of progeny
micewith the same coat color distribution as the original mi-iPSC
parental strain, although the frequency of this occurrence was
low (Figure 1S). Nevertheless, overall we have shown clearly
that we can generate mouse mi-iPSCs that have acquired pluri-
potency via the introduction of synthesized miRNA from mASCs
(Figure 1). We have also been successful in generating mi-iPSCs
fromMEFs, albeit with lower efficiency (one to five colonies from
5 3 105 cells) (data not shown).
To evaluate whether we can also reprogram human cells
using this approach, we transfected mir-200c, mir-302 s, and
mir-369 s into human ASCs (hASCs) and human dermal fibro-
blasts (HDFs) (results summarized in Table S2). Cells seeded
at densities of 13 104 to 53 104 cells/well in 6-well culture plates
were transfected with miRNAs through the same four-cycle
protocol as for mouse cells at 48 hr intervals, and on day 8 the
cells were harvested by trypsinization and transferred to ESC
culture conditions according to methods described previously
(Miyoshi et al., 2010). Twenty days after initial transfection,
some colonies with sharp and defined margins and a different
morphology from parental cells appeared (Figure 2A), at a fre-
quency of two colonies from 1 3 105 adult human cells. We
detected undifferentiated ESC marker gene expression in
these colonies by immunocytochemistry (Figures 2B and 2C).
Real-time RT-PCR revealed that these human mi-iPSCs ex-
pressed ES-like genes, including NANOG, OCT4, SOX2, and
LIN28 (Figure 2D). Using RT-PCR, we also found that hASC-
and HDF-derived mi-iPSCs express high levels of mir-200c,
mir-302 s, and mir-369 s (Figure 2E). The karyotype was pre-
dominantly normal (46 human chromosomes were observed in
10/12 cells [83.3%]; Figure 1T). To examine their differentiations exhibited various morphologies, and immunocytochemistry confirmed the
321), whereas the CpGdinucleotides of the regions weremethylated in parental
ted, respectively).
CID mice, and tumor formation was exhibited in various tissues as epithelial
monstrated that mi-iPSCs contributed to adipose, intestinal, brain, and gonadal
e and parental mouse were used as positive and negative control templates,
ontrol; NC, negative control.
ontribution, as shown in R) with Bulb/c mice resulted in the generation of black
in (the frequency was less than 1/20).
man mi-iPSCs and forty chromosomes in mouse mi-iPSCs are shown.
ification, 3 200.
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Figure 2. Pluripotency-Associated Gene Expression in mi-iPSCs from Human Somatic Cells
(A) At day 20, some colonies with sharp and defined margins appeared that were morphologically different from the parental hASCs and HDFs.
(B and C) Immunocytochemistry revealed mi-iPSCs from hASCs (B) and HDFs (C) expressing Ssea-4, Tra-1-60, Tra-1-81, and Tra-2-49.
(D) The mi-iPSCs from hASCs and HDFs highly expressed undifferentiated ESC-marker genes compared to the observed expression in their respective parental
cells. The expression of mRNA copies was normalized against GAPDH mRNA expression (mean ± SEM; n = 3).
(E) Real-time RT-PCR analysis of miRNAs in parental mi-iPSCs. The expression of miRNA copies was normalized against RNU48 expression, and the mean
expression of hASC mi-iPSC was set to 1 for each gene (mean ± SEM; n = 3).
(F) mi-iPSCs (clone 3621A1) were transplanted subcutaneously into the dorsal flanks of NOD/SCID mice, and teratomas formed in various tissues and cells as
epidermal, ganglia-like, osteoid, skeletal muscle, chondrocyte, and ciliated epithelial tissue (arrow, goblet cell).
See also Figure S2 and Tables S1 and S2. Bar = 100 mm; original magnification, 3 200.
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into the dorsal flanks of NOD/SCID mice. Teratoma formation
was observed in mice 12 weeks postinjection (Figures 2F and
S2F). Histological findings indicated that the tumors contained
various tissues found in the epithelial (endoderm), epidermal
(ectoderm), and adipose (mesoderm) tissues, representing all
three germ layers. Overall, these findings suggest that direct
transfection of mature miRNAs can also induce pluripotency in
human somatic cells, and that these miRNA properties are
conserved across species.636 Cell Stem Cell 8, 633–638, June 3, 2011 ª2011 Elsevier Inc.Our findings are consistent with previous analyses of miRNA
function in pluripotent cells. Microarray analysis indicated that
the promoter region of mir-302 s was conserved across species
and driven by the transcription factor Oct4 (Marson et al., 2008).
Members of the mir-302 s family were investigated as important
key factors in the maintenance of ESC renewal and pluripotency
as zygotic inhibitors of premature cell differentiation during early
embryonic development (Rosa andBrivanlou, 2011). TargetScan
(http://www.targetscan.org/) prediction for the mir-302 s family
indicated that they inhibit the amine oxidase domain 1 (Aof1)
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MicroRNAs Induce Pluripotent Stem Cellsgene, which is associated with DNA methylation (Ciccone et al.,
2009; Gregory et al., 2008). We found that Aof1 was specifically
repressed in mi-iPSCs, but not in parental cells (data not shown).
During the course of reprogramming by defined factors, the
morphology of somatic fibroblasts changed after cell-to-cell
interactions, and iPSCs begin expressing E-cadherin, an epithe-
lial cell marker highly expressed in ESCs (Gregory et al., 2008).
These reports support our experimental results with mir-200c,
which represses the epithelial-mesenchymal transition by inhib-
iting TGFb signaling and is highly expressed in epithelial cells
(Gregory et al., 2008). TargetScan prediction for mir-369 s also
indicates that it inhibits ZEB2-related TGFb signaling (Grimson
et al., 2007) (data not shown). In our study, we could not generate
GFP-positive colonies inmASCs fromNanog reportermice using
transfection of only one or two of these miRNAs. We concluded
that all three of these factors are essential to generate PSCs from
somatic cells. Other potential combinations of miRNAs that may
also be able to generate pluripotent cells from somatic cells
remain to be assessed.
Most of the reprogramming methods reported so far involve
introduction of genetic materials and thus run the risk that exog-
enous vector sequences can be integrated into the host genome
(Okita et al., 2008; Kaji et al., 2009; Woltjen et al., 2009; Jia et al.,
2010). Very recently, highly efficient miRNA-mediated reprog-
ramming of mouse and human somatic cells to pluripotency
was reported (Anokye-Danso et al., 2011), but using integrating
viral vectors and not direct transfection of mature miRNAs.
Previous studies have also indicated that mir-302 s has reprog-
ramming activity in human cells (Lin et al., 2011). Our study uses
a different methodological approach, direct transfection of
mature miRNAs, that has benefits from the perspective of poten-
tial clinical translation, although it does operate at considerably
lower efficiency. We have successfully generated mi-iPSCs
using this protocol more than six times. The resulting mi-iPSCs
are subject to a reduced risk of mutations and tumorigenesis
relative to most other protocols because mature miRNAs func-
tion without vectors or genomic integration. We also note that
miRNA-based approaches are already under direct clinical
investigation in a number of other therapeutic contexts. For
example, a recent report demonstrated the utility and safety of
therapy with miRNA in the treatment of hepatitis C (Lanford
et al., 2010). We hope that mi-iPSC generation will eventually
prove to be of significant benefit for both biochemical research
and clinical regenerative medicine.
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